Click here to get full coverage on Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials - TipRanks

Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials  TipRanks

Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials - TipRanks

Click here to get full coverage on RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Yahoo Finance

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint  Yahoo Finance

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Yahoo Finance

Click here to get full coverage on Brittle bone drug trial falls short on fractures but boosts bone density - Stock Titan

Brittle bone drug trial falls short on fractures but boosts bone density  Stock Titan

Brittle bone drug trial falls short on fractures but boosts bone density - Stock Titan

Click here to get full coverage on Jefferies downgrades Mereo Biopharma Group Plc (MREO) to a Hold - The Globe and Mail

Jefferies downgrades Mereo Biopharma Group Plc (MREO) to a Hold  The Globe and Mail

Jefferies downgrades Mereo Biopharma Group Plc (MREO) to a Hold - The Globe and Mail

Click here to get full coverage on Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com

Mereo BioPharma stock plummets after failed Phase 3 trials  Investing.com

Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com

Click here to get full coverage on Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials - Quiver Quantitative

Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials  Quiver Quantitative

Mereo BioPharma Stock (MREO) Opinions on Failed Phase 3 Trials - Quiver Quantitative

Click here to get full coverage on Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat

Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO)  MarketBeat

Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat

Click here to get full coverage on RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint  Finviz

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz

Click here to get full coverage on These biotech stocks are getting hammered by shocking brittle-bone treatment study results - MarketWatch

These biotech stocks are getting hammered by shocking brittle-bone treatment study results  MarketWatch

These biotech stocks are getting hammered by shocking brittle-bone treatment study results - MarketWatch

Click here to get full coverage on BTIG Lowers Price Target for Mereo BioPharma Group (MREO) to $1.00 | MREO Stock News - GuruFocus

BTIG Lowers Price Target for Mereo BioPharma Group (MREO) to $1.00 | MREO Stock News  GuruFocus

BTIG Lowers Price Target for Mereo BioPharma Group (MREO) to $1.00 | MREO Stock News - GuruFocus

Click here to get full coverage on New Analyst Forecast: $MREO Given $1 Price Target - Quiver Quantitative

New Analyst Forecast: $MREO Given $1 Price Target  Quiver Quantitative

New Analyst Forecast: $MREO Given $1 Price Target - Quiver Quantitative

Click here to get full coverage on We're Interested To See How Mereo BioPharma Group (NASDAQ:MREO) Uses Its Cash Hoard To Grow - Yahoo Finance

We're Interested To See How Mereo BioPharma Group (NASDAQ:MREO) Uses Its Cash Hoard To Grow  Yahoo Finance

We're Interested To See How Mereo BioPharma Group (NASDAQ:MREO) Uses Its Cash Hoard To Grow - Yahoo Finance

Click here to get full coverage on MREO Stock Sees Major Downgrade as Jefferies Cuts Price Target | - GuruFocus

MREO Stock Sees Major Downgrade as Jefferies Cuts Price Target |  GuruFocus

MREO Stock Sees Major Downgrade as Jefferies Cuts Price Target | - GuruFocus

Click here to get full coverage on MREO Downgraded to Market Perform by LifeSci Capital | MREO Stoc - GuruFocus

MREO Downgraded to Market Perform by LifeSci Capital | MREO Stoc  GuruFocus

MREO Downgraded to Market Perform by LifeSci Capital | MREO Stoc - GuruFocus

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail

Click here to get full coverage on Mereo BioPharma (MREO) Reports Phase 3 Results for Setrusumab in Osteogenesis Imperfecta - GuruFocus

Mereo BioPharma (MREO) Reports Phase 3 Results for Setrusumab in Osteogenesis Imperfecta  GuruFocus

Mereo BioPharma (MREO) Reports Phase 3 Results for Setrusumab in Osteogenesis Imperfecta - GuruFocus

Click here to get full coverage on DigitalBridge downgraded, Commvault initiated: Wall Street’s top analyst calls - The Globe and Mail

DigitalBridge downgraded, Commvault initiated: Wall Street’s top analyst calls  The Globe and Mail

DigitalBridge downgraded, Commvault initiated: Wall Street’s top analyst calls - The Globe and Mail

Click here to get full coverage on Lost Money on Mereo BioPharma Group plc (MREO)? Possible Fraud - Contact Levi & Korsinsky Today - ACCESS Newswire

Lost Money on Mereo BioPharma Group plc (MREO)? Possible Fraud - Contact Levi & Korsinsky Today  ACCESS Newswire

Lost Money on Mereo BioPharma Group plc (MREO)? Possible Fraud - Contact Levi & Korsinsky Today - ACCESS Newswire

Click here to get full coverage on Mereo BioPharma Group plc Announces Phase 3 Study Results for Setrusumab - TradingView — Track All Markets

Mereo BioPharma Group plc Announces Phase 3 Study Results for Setrusumab  TradingView — Track All Markets

Mereo BioPharma Group plc Announces Phase 3 Study Results for Setrusumab - TradingView — Track All Markets

Click here to get full coverage on This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga

This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday  Benzinga

This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga

Click here to get full coverage on Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat

Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO)  MarketBeat

Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat

Click here to get full coverage on Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - FinancialContent

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO  FinancialContent

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - FinancialContent

Click here to get full coverage on Why Are Ultragenyx And Mereo Stocks Sinking Monday? - Mereo BioPharma Group (NASDAQ:MREO), Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga

Why Are Ultragenyx And Mereo Stocks Sinking Monday? - Mereo BioPharma Group (NASDAQ:MREO), Ultragenyx Pharmaceutical (NASDAQ:RARE)  Benzinga

Why Are Ultragenyx And Mereo Stocks Sinking Monday? - Mereo BioPharma Group (NASDAQ:MREO), Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga

Click here to get full coverage on Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - MarketBeat

Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC  MarketBeat

Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - MarketBeat

Click here to get full coverage on Merger Talk: Why analysts remain bullish on MREO stock - Market Volume Report & Consistent Profit Trading Strategies - moha.gov.vn

Merger Talk: Why analysts remain bullish on MREO stock - Market Volume Report & Consistent Profit Trading Strategies  moha.gov.vn

Merger Talk: Why analysts remain bullish on MREO stock - Market Volume Report & Consistent Profit Trading Strategies - moha.gov.vn

Click here to get full coverage on Mereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Tema Etfs LLC - MarketBeat

Mereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Tema Etfs LLC  MarketBeat

Mereo BioPharma Group plc - Sponsored ADR $MREO Shares Sold by Tema Etfs LLC - MarketBeat

Click here to get full coverage on BTIG Research Reaffirms "Buy" Rating for Mereo BioPharma Group (NASDAQ:MREO) - MarketBeat

BTIG Research Reaffirms "Buy" Rating for Mereo BioPharma Group (NASDAQ:MREO)  MarketBeat

BTIG Research Reaffirms "Buy" Rating for Mereo BioPharma Group (NASDAQ:MREO) - MarketBeat

Click here to get full coverage on MREO: Needham Reiterates 'Buy' Rating, Price Target Unchanged at - GuruFocus

MREO: Needham Reiterates 'Buy' Rating, Price Target Unchanged at  GuruFocus

MREO: Needham Reiterates 'Buy' Rating, Price Target Unchanged at - GuruFocus

Click here to get full coverage on RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Nasdaq

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End  Nasdaq

RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Nasdaq

Click here to get full coverage on MREO: BTIG Reiterates Buy Rating with $6.00 Price Target | MREO Stock News - GuruFocus

MREO: BTIG Reiterates Buy Rating with $6.00 Price Target | MREO Stock News  GuruFocus

MREO: BTIG Reiterates Buy Rating with $6.00 Price Target | MREO Stock News - GuruFocus

Click here to get full coverage on Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session  Benzinga

Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Click here to get full coverage on Is Mereo BioPharma Group on the Rise? - StocksToTrade

Is Mereo BioPharma Group on the Rise?  StocksToTrade

Is Mereo BioPharma Group on the Rise? - StocksToTrade

Click here to get full coverage on Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com

Mereo BioPharma stock price target cut by BTIG to $1 from $6  Investing.com

Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com

Click here to get full coverage on Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Yahoo Finance

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143  Yahoo Finance

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Yahoo Finance

Click here to get full coverage on Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat

Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO)  MarketBeat

Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat

Click here to get full coverage on Mereo Biopharma Updates Setrusumab Trials and Cost Controls - TipRanks

Mereo Biopharma Updates Setrusumab Trials and Cost Controls  TipRanks

Mereo Biopharma Updates Setrusumab Trials and Cost Controls - TipRanks

Click here to get full coverage on Mereo BioPharma Group plc (MREO): A Bull Case Theory - Yahoo Finance

Mereo BioPharma Group plc (MREO): A Bull Case Theory  Yahoo Finance

Mereo BioPharma Group plc (MREO): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Yahoo Finance

Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance

Click here to get full coverage on Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Rating of "Moderate Buy" by Brokerages  MarketBeat

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch - Yahoo Finance

Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch  Yahoo Finance

Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch - Yahoo Finance

Click here to get full coverage on Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com

Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure  Investing.com

Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com

Click here to get full coverage on Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com

Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data  Investing.com

Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com

Click here to get full coverage on Mereo BioPharma Group plc (NASDAQ:MREO): Is Breakeven Near? - Yahoo Finance

Mereo BioPharma Group plc (NASDAQ:MREO): Is Breakeven Near?  Yahoo Finance

Mereo BioPharma Group plc (NASDAQ:MREO): Is Breakeven Near? - Yahoo Finance

Click here to get full coverage on Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - Yahoo Finance

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights  Yahoo Finance

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - Yahoo Finance

Click here to get full coverage on Mereo BioPharma stock price target cut by BTIG to $1 from $6 By Investing.com - Investing.com Canada

Mereo BioPharma stock price target cut by BTIG to $1 from $6 By Investing.com  Investing.com Canada

Mereo BioPharma stock price target cut by BTIG to $1 from $6 By Investing.com - Investing.com Canada

Click here to get full coverage on Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI (MREO) - Seeking Alpha

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI (MREO)  Seeking Alpha

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI (MREO) - Seeking Alpha

Click here to get full coverage on In the wake of Mereo BioPharma Group plc's (NASDAQ:MREO) latest US$200m market cap drop, institutional owners may be forced to take severe actions - simplywall.st

In the wake of Mereo BioPharma Group plc's (NASDAQ:MREO) latest US$200m market cap drop, institutional owners may be forced to take severe actions  simplywall.st

In the wake of Mereo BioPharma Group plc's (NASDAQ:MREO) latest US$200m market cap drop, institutional owners may be forced to take severe actions - simplywall.st

Click here to get full coverage on Rare Earths Oxide Produced From Halleck Creek Ore - The Globe and Mail

Rare Earths Oxide Produced From Halleck Creek Ore  The Globe and Mail

Rare Earths Oxide Produced From Halleck Creek Ore - The Globe and Mail

Click here to get full coverage on Here's Why We're Not At All Concerned With Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - simplywall.st

Here's Why We're Not At All Concerned With Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation  simplywall.st

Here's Why We're Not At All Concerned With Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Situation - simplywall.st

Click here to get full coverage on We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate - Yahoo Finance

We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate  Yahoo Finance

We're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn Rate - Yahoo Finance

Click here to get full coverage on Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com Nigeria

Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com  Investing.com Nigeria

Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com Nigeria

Click here to get full coverage on Ultragenyx and Mereo shares plunge as brittle bone drug trial stays on course - The Pharma Letter

Ultragenyx and Mereo shares plunge as brittle bone drug trial stays on course  The Pharma Letter

Ultragenyx and Mereo shares plunge as brittle bone drug trial stays on course - The Pharma Letter

Click here to get full coverage on Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha

Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect  Seeking Alpha

Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha

Click here to get full coverage on JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com

JPMorgan maintains Mereo BioPharma stock rating despite trial setback  Investing.com

JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com

Click here to get full coverage on Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire

Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights  GlobeNewswire

Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire

Click here to get full coverage on BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data - Investing.com

BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data  Investing.com

BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data - Investing.com

Click here to get full coverage on Mereo BioPharma’s Unexpected Slide: A Buying Opportunity? - timothysykes.com

Mereo BioPharma’s Unexpected Slide: A Buying Opportunity?  timothysykes.com

Mereo BioPharma’s Unexpected Slide: A Buying Opportunity? - timothysykes.com

Click here to get full coverage on Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative

Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta  Quiver Quantitative

Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - PR Newswire

Click here to get full coverage on Press Release - Mining.com

Press Release - Mining.com

Click here to get full coverage on BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress - Investing.com

BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress  Investing.com

BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress - Investing.com

Click here to get full coverage on Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - Seeking Alpha

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy  Seeking Alpha

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - Seeking Alpha

Click here to get full coverage on Leerink Partners maintains Outperform rating on Ultragenyx stock despite trial failures By Investing.com - Investing.com Nigeria

Leerink Partners maintains Outperform rating on Ultragenyx stock despite trial failures By Investing.com  Investing.com Nigeria

Leerink Partners maintains Outperform rating on Ultragenyx stock despite trial failures By Investing.com - Investing.com Nigeria

Click here to get full coverage on Buying Mereo BioPharma After JPMorgan's Boosts Price Target - TheStreet Pro

Buying Mereo BioPharma After JPMorgan's Boosts Price Target  TheStreet Pro

Buying Mereo BioPharma After JPMorgan's Boosts Price Target - TheStreet Pro

Click here to get full coverage on Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) - Seeking Alpha

Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO)  Seeking Alpha

Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) - Seeking Alpha

Click here to get full coverage on Verde AgriTech Confirms Ionic Adsorption with High-Value - GlobeNewswire

Verde AgriTech Confirms Ionic Adsorption with High-Value  GlobeNewswire

Verde AgriTech Confirms Ionic Adsorption with High-Value - GlobeNewswire

Click here to get full coverage on Clay-Hosted Discovery Delivers High-Grade Rare Earth Intercepts From Surface - The Globe and Mail

Clay-Hosted Discovery Delivers High-Grade Rare Earth Intercepts From Surface  The Globe and Mail

Clay-Hosted Discovery Delivers High-Grade Rare Earth Intercepts From Surface - The Globe and Mail

Click here to get full coverage on CORRECTION - Verde AgriTech Announces District Scale - GlobeNewswire

CORRECTION - Verde AgriTech Announces District Scale  GlobeNewswire

MREO

Price Chart

Key Statistics

Technicals

About MREO

Latest News

Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials - TipRanks

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Yahoo Finance

Brittle bone drug trial falls short on fractures but boosts bone density - Stock Titan

Advanced Charts

Top Gainers

Top Losers